Study clarifies a key step in Andes virus infection
Researchers at Albert Einstein College of Medicine and collaborating institutions have described how Andes virus recognizes a receptor on the surface of human cells. The work, published in Nature, focuses on PCDH1, a cell-surface protein the team had previously identified as necessary for infection.
The finding addresses a central question in the biology of Andes virus: not simply which human-cell protein it uses, but how the virus physically captures that target. According to the researchers, the newly described interaction reveals an unusual way for a virus to engage a receptor during infection and could point toward therapies designed around that vulnerability.
Andes virus belongs to the hantavirus family, a group carried mainly by rodents. Some hantaviruses can cause hantavirus pulmonary syndrome, a severe respiratory disease that can progress rapidly to breathing failure. People are generally infected after inhaling virus particles associated with infected rodents’ urine, droppings, or saliva.
Why Andes virus draws particular concern
More than 20 hantaviruses are known to cause disease in people, but Andes virus has a distinctive and consequential feature: it is the only one known to spread from person to person. The source report says this transmission usually occurs through close and prolonged contact.
That capability came into sharp focus during an outbreak earlier in 2026 on a cruise ship. The outbreak killed three passengers and sickened 13 others, according to the report. It also underscored a practical gap: there are no approved vaccines or treatments for the virus.
The new work does not announce a treatment or a vaccine. Instead, it supplies a more detailed map of an early biological event that therapies may eventually seek to interrupt. This distinction matters. Understanding how a pathogen enters cells can make a drug-development target more concrete, but it is not by itself evidence that a medicine will work in people.
PCDH1 as the point of contact
Viruses must gain access to cells to reproduce. For Andes virus, that process begins with a spike protein on the virus surface binding to PCDH1 on a human cell. The Einstein-led team had shown eight years earlier that the virus uses this receptor, but had not determined the precise recognition mechanism.
In the new study, the researchers examined the attachment process and described how the viral spike captures PCDH1. An image released with the study shows cells infected with a research virus model and PCDH1 bound to them. The work gives scientists a structural and mechanistic starting point for considering ways to block the interaction before infection proceeds.
That is particularly relevant for a virus family in which severe disease can develop quickly. A therapy that prevents a virus from binding its receptor would aim at a very early stage of infection. The study’s authors say the result may suggest approaches against Andes virus as well as other hantaviruses.
From mechanism to medical use
Basic virology studies can seem remote from clinical care, but receptor research often shapes the earliest stages of therapeutic design. Once scientists can describe a vulnerable interaction between a virus and a human-cell receptor, they can investigate whether that interaction can be disrupted by antibodies, engineered proteins, or other treatment strategies.
Those follow-on questions remain open for Andes virus. The source material supports the conclusion that the study identifies a potential therapeutic direction; it does not establish an approved intervention, a candidate’s safety, or a timeline for use. Any future treatment would still need substantial testing.
For now, the value of the research is its clarification of a biological puzzle that had persisted since PCDH1 was first linked to Andes virus infection. The result narrows the uncertainty around how the pathogen recognizes susceptible human cells and gives researchers a defined interaction to study further.
A broader lesson from the outbreak
The cruise-ship outbreak described in the report illustrates why detailed work on viral entry can have real urgency. A pathogen capable of person-to-person spread presents a different set of containment and treatment challenges than one transmitted only from an animal reservoir. In the absence of approved vaccines or treatments, prevention and a better understanding of transmission remain especially important.
The researchers’ work does not resolve those wider public-health challenges, but it adds a useful piece to the scientific foundation needed to address them. By showing how Andes virus captures PCDH1, the study provides a clearer account of the first contact between virus and host cell—and a possible opening for future countermeasures.
This article is based on reporting by Phys.org. Read the original article.
Originally published on phys.org
